Apellis Pharmaceuticals (NASDAQ:APLS) and 180 Life Sciences (NASDAQ:ATNF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.
This is a summary of recent recommendations and price targets for Apellis Pharmaceuticals and 180 Life Sciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|180 Life Sciences||0||0||0||0||N/A|
Institutional and Insider Ownership
81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of 180 Life Sciences shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 73.5% of 180 Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Apellis Pharmaceuticals and 180 Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|180 Life Sciences||N/A||-94.05%||-38.77%|
Risk and Volatility
Apellis Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of -0.55, meaning that its share price is 155% less volatile than the S&P 500.
Valuation & Earnings
This table compares Apellis Pharmaceuticals and 180 Life Sciences’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Apellis Pharmaceuticals||N/A||N/A||-$304.71 million||($4.64)||-8.95|
|180 Life Sciences||N/A||N/A||-$90,000.00||N/A||N/A|
Apellis Pharmaceuticals beats 180 Life Sciences on 5 of the 9 factors compared between the two stocks.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.
About 180 Life Sciences
180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. It operates as a clinical-stage biotechnology company focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded in 2016 and is headquartered in Menlo Park, CA.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.